The Technical Analyst
Bellicum Pharmaceuticals [BLCM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bellicum Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.68% $0.0748
America/New_York / 4 mar 2024 @ 14:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.778 mill |
| EPS: | -0.670 |
| P/E: | -0.112 |
| Earnings Date: | Mar 29, 2024 |
| SharesOutstanding: | 10.41 mill |
| Avg Daily Volume: | 0.0286 mill |
| RATING 2024-03-04 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.112 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.112 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0548 - 0.0948 ( +/- 26.76%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-22 | Baker Bros. Advisors Lp | Sell | 1 941 607 | Warrants (right to buy) |
| 2023-11-22 | Baker Bros. Advisors Lp | Buy | 1 941 607 | Common Stock |
| 2023-11-22 | Baker Bros. Advisors Lp | Sell | 174 742 | Warrants (right to buy) |
| 2023-11-22 | Baker Bros. Advisors Lp | Buy | 174 742 | Common Stock |
| 2023-05-05 | Baker Bros. Advisors Lp | Buy | 0 | Common Stock |
| INSIDER POWER |
|---|
| 9.70 |
| Last 91 transactions |
| Buy: 8 287 527 | Sell: 2 332 728 |
Forecast:
16:00 - $0.0748
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0748 (-6.68% ) |
| Volume | 0.0061 mill |
| Avg. Vol. | 0.0286 mill |
| % of Avg. Vol | 21.20 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLCM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BLCM
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Latest Press Releases
2023-03-14 16:30:00 - Press Release
Bellicum Discontinues Phase 1/2 Trials And Initiates Evaluation Of Strategic Alternatives
Houston, march 14, 2023 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), today announced its decision to discontinue its ongoing phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its gocar-t cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. the trials for bpx-601 and bpx-603 are being discontinued following the company's assessment of the risk/benefit profile of bpx-601 in combination with rimiducid.
2023-01-31 18:43:00 - Press Release
Correction -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Houston, jan. 31, 2023 (globe newswire) -- in a release issued earlier today by bellicum pharmaceuticals, inc. (nasdaq:blcm), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. the corrected release follows:
2023-01-31 16:36:00 - Press Release
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Houston, jan. 31, 2023 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. the compensation committee of the board of directors approved the grants with an effective date of january 31, 2023. the stock options were granted as inducements material to the employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
2023-01-19 07:30:00 - Press Release
Bellicum Pharmaceuticals To Present Early Phase 1 Results For Bpx-601 In Prostate Cancer At Asco 2023 Genitourinary Cancers Symposium
Houston, jan. 19, 2023 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a phase 1 clinical trial for bpx-601, its lead gocar-t® product candidate, has been accepted for poster presentation at the 2023 american society of clinical oncology genitourinary cancers symposium (asco gu). the meeting is being held february 16-18, 2023 in san francisco and virtually. the ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.
2022-12-11 10:00:00 - Press Release
Bellicum Announces Presentation By Unc At Ash 2022 On Potential Abrogation Of Ic9 Car T-cell Toxicities With Rimiducid
Houston, dec. 11, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the university of north carolina lineberger comprehensive cancer center (unc lineberger) team at the 64th american society of hematology (ash) annual meeting and exposition being held in new orleans december 10-13, 2022. the presentation, scheduled for today at 6 p.m. ct, will provide data on four patients who received rimiducid to activate the caspacide® safety switch in an investigator sponsored trial.
Latest News
2023-03-16 13:00:28 - Zacks Investment Research
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
2023-02-27 11:17:47 - Zacks Investment Research
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
2023-01-19 07:30:00 - GlobeNewsWire
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.
2022-09-01 07:30:00 - GlobeNewsWire
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
2021-09-03 07:30:00 - GlobeNewsWire
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.
2021-09-01 08:22:43 - Pulse2
BLCM Stock: Over 12% Increase Pre-Market Explanation
The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.
2021-09-01 07:30:00 - GlobeNewsWire
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum's CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.
2021-07-26 17:25:00 - GlobeNewsWire
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grant with an effective date of July 26, 2021. The stock options were granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
2021-06-28 07:30:00 - GlobeNewsWire
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company's CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid. CaspaCIDe may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs.
2021-05-17 07:30:00 - GlobeNewsWire
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.